Heptromic. Genomic predictors and oncogenic drivers in hepatocellurlar carcinoma

  • Heptromic Genomic predictors and oncogenic drivers in hepatocellular carcinoma. Watch the video
  • Heptromic will optimise decision-making for liver cancer patients by identifying genomic prognostic determinants and oncogenic drivers.
  • Heptromic’s core team comprises leading European researchers in the basic, translational and clinical fields of liver cancer.
  • Heptromic is a 3-year translational research project which aims to solve core problems in the management of hepatocellular carcinoma (HCC), the third most common cause of cancer-related death worldwide.


  • IDIBAPS participates in a new international project to advance in translational cancer research

    Josep M. Llovet participates in the HUNTER (Hepatocellular Carcinoma Expediter Network) project, which is led by the University of Newcastle and granted with 5.6 million euros. Prof Llovet’s group at IDIBAPS has been granted with 1 million euros, this is the only Spanish group that participates in the Accelerator Award. In addition to the IDIBAPS group, 11 international research groups from the United Kingdom and 5 expert groups in hepatocellular carcinoma in Italy participate in this international project. This is the most important private funding ever granted in Europe for liver cancer research. Prof. Josep M Llovet - principal investigator - and Dr. Roser Pinyol - scientific project coordinator, collected the award at the event organized by the AECC in Madrid on September 24th 2018.

  • IDIBAPS researchers review advances in the treatment of liver cancer at Nature Reviews

    Prof Josep M Llovet and Dr Robert Montal IDIBAPS researchers, have published an article in the Journal Nature Reviews of Clinical Oncology in which they review the important advances that have taken place in the treatment of hepatocellular carcinoma (HCC). The article analyzes the different molecular targets, new therapies and future perspectives in the treatment of this cancer, which accounts for 90% of primary liver tumors.

More news



More events


Scientific Publications

More scientific publications

Heptromic Partners

Institut National de la Santé et de la Recherche Médicale

Prof. Jessica Zucman-Rossi

Institut National de la Santé et de la Recherche Médicale

Prof. Jessica Zucman-Rossi

Next generation sequencing

Project led by: Idibaps

Copyright © 2010 - 2019 HEPTROMIC

HEPTROMIC is a project in the 'Health' Theme of the Specific Programme 'Cooperation' of the European Commission's Seventh Framework Programme.